KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new interim results from its KONFIDENT-KID clinical trial ...

Hereditary angioedema (HAE) is a rare genetic condition that causes swelling under the skin and lining of your gut and lungs. “Angio” means it affects your blood vessels. “Edema” means swelling. So ...

KalVista Pharmaceuticals recently reported interim results from its KONFIDENT-KID trial, showing that oral EKTERLY (sebetralstat) provided rapid, well-tolerated on-demand treatment for 172 hereditary ...

Please provide your email address to receive an email when new articles are posted on . The patient, aged 66 years, had no previous edema. The patient tested positive for a mutation in the plasminogen ...

An update from Pharvaris ( (PHVS) ) is now available.

A single dose of the CRISPR-based gene-editing therapy NTLA-2002 significantly reduced angioedema attacks compared with placebo in patients with hereditary angioedema, according to results from a ...

Please provide your email address to receive an email when new articles are posted on . Children took daily doses of berotralstat that ranged from 78 mg to 150 mg. There were no grade 3 or 4 adverse ...

ORLANDO -- Long-term results from trials of new drugs for hereditary angioedema (HAE) continue to support efficacy and safety, researchers reported at the American College of Allergy, Asthma & ...

PHILADELPHIA — The investigational drug navenibart reduced attacks of hereditary angioedema by an average 91% over 1 year with only twice-yearly dosing and no serious adverse effects or safety signals ...

T he severe swelling of hereditary angioedema (HAE) can be uncomfortable and inconvenient at best, life-threatening at worst. What’s more, symptoms are unpredictable, vary in severity, and crop up out ...